|
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients |
Sanchez-de la Rosa R, Herrera L, Moreno S |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Sanchez-de la Rosa R, Herrera L, Moreno S. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Clinical Therapeutics 2008; 30(2): 372-381 Indexing Status Subject indexing assigned by NLM MeSH Adenine /analogs & Anti-HIV Agents /economics /therapeutic use; Antiretroviral Therapy, Highly Active; Benzoxazines /economics /therapeutic use; Cost-Benefit Analysis; Decision Trees; Deoxycytidine /analogs & Drug Costs; Emtricitabine; HIV Infections /drug therapy /economics /virology; HIV-1; Health Care Costs; Health Resources /economics /utilization; Humans; Lamivudine /economics /therapeutic use; Models, Economic; Organophosphonates /economics /therapeutic use; Reverse Transcriptase Inhibitors /economics /therapeutic use; Tenofovir; Time Factors; Treatment Outcome; Zidovudine /economics /therapeutic use; derivatives /economics /therapeutic use; derivatives /economics /therapeutic use AccessionNumber 22008000787 Date bibliographic record published 09/08/2008 |
|
|
|